Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADM03820 for Prevention of Symptomatic COVID-19
NCT05142527Phase 3Withdrawn
- Sponsor
- Resilience Government Services
- Start
- Jan 2023
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing ADM03820 with Placebo (2 arms). Primary endpoints: Incidence and severity of reactogenicity and adverse events at Day 540 and Incidence of symptomatic, virologically confirmed COVID-19 at Day 29. Planned start Jan 2023; status: withdrawn.
02
Drugs
ADM03820
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05142527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05142527.